Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34235422
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Current evidence for directed and supportive investigational therapies against
COVID-19
#MMPMID34235422
van Rensburg R
; Pillay-Fuentes Lorente V
; Decloedt EH
Afr J Thorac Crit Care Med
2020[]; 26
(2
): ? PMID34235422
show ga
Coronavirus disease 2019 (COVID-19) is a global health crisis. There is currently
a great need for effective and safe therapies directed at the disease, but no
drugs are presently registered for use in COVID-19. Several directed therapies
have been proposed, and most are still in clinical trials. Currently available
published, peer-reviewed results mostly involve small sample sizes with study
limitations restricting the interpretation of the findings. Many trials currently
published also do not have a control group, limiting the interpretation of the
effect of the intervention. Investigational directed therapies as well as
investigational supportive therapies against COVID-19 are reviewed here.
Chloroquine and hydroxychloroquine show promise as directed therapies, but
current trial results are conflicting. Lopinavir/ritonavir also shows potential,
but was started late in the disease course in most trials. No randomised
controlled evidence is currently available for remdesivir and favipiravir.
Corticosteroid use is not recommended for directed therapy against COVID-19, and
the role of tocilizumab is currently unclear, based on limited evidence. Early
initiation of investigational directed therapies may provide benefit in selected
patients. The results from larger randomised controlled trials will clarify the
place of these therapies in COVID-19 treatment.
free
free
free
